Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study
{{output}}
Background and objective: HPP737, a novel phosphodiesterase 4 (PDE4) inhibitor, was designed to treat chronic obstructive pulmonary disease (COPD). This study aimed to evaluate its pharmacokinetics, safety and tolerability in hea... ...
